Immatics is a holding company. Through its subsidiaries, Co. is engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer patients. Co.'s focus is the generation of therapeutic options for solid tumor patients. Co. is developing its targeted immunotherapy product candidates via two treatment modalities: Adoptive Cell Therapies (ACT) and antibody-like Bispecifics. Co.'s clinical product class ACTengine is based on genetically modifying a patient's own T cells to express a proprietary TCR. Co.'s TCR Bispecifics are consisting of a portion of the TCR that recognizes cancer cells and a T cell recruiter domain that recruits and activates T cells. The IMTX stock yearly return is shown above.
The yearly return on the IMTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IMTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|